Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CALEC for Limbal Stem Cell Deficiency
NCT02592330Phase 2Completed
- Sponsor
- Massachusetts Eye and Ear
- Start
- Aug 2016
- Primary completion
- Mar 2023
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of cultivated autologous limbal epithelial cells in limbal stem cell deficiency (LSCD), sponsored by Massachusetts Eye and Ear. Started Aug 2016; status: completed.
02
Drugs
cultivated autologous limbal epithelial cells
03
Conditions
limbal stem cell deficiency (LSCD)
Beyond the preview
Go deeper on NCT02592330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02592330.